| Display title | University College London Hospitals v KG [2018] EWCOP 29 |
| Default sort key | University College London Hospitals v KG (2018) EWCOP 29 |
| Page length (in bytes) | 745 |
| Page ID | 9599 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Edit | Allow only users with "editing" permission (infinite) |
| Move | Allow only users with "editing" permission (infinite) |
| Page creator | Jonathan (talk | contribs) |
| Date of page creation | 22:26, 31 October 2018 |
| Latest editor | Jonathan (talk | contribs) |
| Date of latest edit | 15:06, 19 February 2019 |
| Total number of edits | 3 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | "In this case the University College London Hospitals NHS Foundation Trust seeks the court's authority to administer a treatment known as PRN100 to a patient KG. KG is represented by the Official Solicitor. KG, the Official Solicitor on his behalf, his family and the Trust all ask for the court's approval. The matter is before the court because PRN100 has never been tested on or administered to any person anywhere. It is thus a completely novel treatment." |
